UK drugs strategy: promised new approach is identical to previous strategies Post date 21 December 2021 ← Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer → Convergence of zero carbon healthcare with patient blood management